DOCSLIB.ORG

S Clone in Igm-MGUS and Waldenstro¨M’S Macroglobulinemia: New Criteria for Differential Diagnosis and Risk Stratification

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
S Clone in Igm-MGUS and Waldenstro¨M’S Macroglobulinemia: New Criteria for Differential Diagnosis and Risk Stratification Leukemia (2014) 28, 166–173 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE Multiparameter flow cytometry for the identification of the Waldenstro¨m’s clone in IgM-MGUS and Waldenstro¨m’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification B Paiva1,2, MC Montes1, R Garcı´a-Sanz1,2, EM Ocio1,2, J Alonso1, N de las Heras3, F Escalante3, R Cuello4, AG de Coca4, J Galende5, J Herna´ndez6, M Sierra7, A Martin1, E Pardal8,ABa´rez9, J Alonso10, L Suarez11, TJ Gonza´lez-Lo´ pez12, JJ Perez1, A Orfao2,13, M-B Vidrı´ales1,2 and JF San Miguel1,2 Although multiparameter flow cytometry (MFC) has demonstrated clinical relevance in monoclonal gammopathy of undetermined significance (MGUS)/myeloma, immunophenotypic studies on the full spectrum of Waldenstro¨m’s Macroglobulinemia (WM) remain scanty. Herein, a comprehensive MFC analysis on bone marrow samples from 244 newly diagnosed patients with an immunoglobulin M (IgM) monoclonal protein was performed, including 67 IgM-MGUS, 77 smoldering and 100 symptomatic WM. Our results show a progressive increase on the number and light-chain-isotype-positive B-cells from IgM-MGUS to smoldering and symptomatic WM (Po.001), with only 1% of IgM-MGUS patients showing 410% B cells or 100% light-chain-isotype-positive B-cells (Po.001). Complete light-chain restriction of the B-cell compartment was an independent prognostic factor for time-to progression in smoldering WM (median 26 months; HR: 19.8, P ¼ 0.001) and overall survival in symptomatic WM (median 44 months; HR: 2.6, P ¼ 0.004). The progressive accumulation of light-chain-isotype-positive B-cells accompanied the emergence of a characteristic Waldenstrom’s phenotype (CD22 þ dim/CD25 þ /CD27 þ /IgM þ ) that differed from other B-NHL by negative expression of CD5, CD10, CD11c or CD103. In contrast to myeloma, light-chain-isotype-positive plasma cells in IgM monoclonal gammopathies show otherwise normal antigenic expression. Our results highlight the potential value of MFC immunophenotyping for the characterization of the Waldenstro¨m’s clone, as well as for the differential diagnosis, risk of progression and survival in WM. Leukemia (2014) 28, 166–173; doi:10.1038/leu.2013.124 Keywords: Waldenstrom’s Macroglobulinemia; MGUS; flow cytometry; phenotype; plasma cells; survival INTRODUCTION there is some controversy to distinguish between smoldering WM The WHO defines Waldenstro¨m’s Macroglobulinemia (WM) as a and IgM-MGUS; some groups use the amount of serum 6 lymphoplasmacytic lymphoma associated with a monoclonal concentration of the M-protein and BM infiltration, while a immunoglobulin M (IgM) protein (regardless of size) and bone consensus panel defined BM disease involvement on histological examination as the main criterion.2 It is plausible to assume that marrow (BM) infiltration by small lymphocytes that may exhibit 7 plasma cell (PC) differentiation.1 As lymphoplasmacytic lymphoma similarly to multiple myeloma (MM), most (if not all) WM patients have eventually gone through the benign stages of IgM-MGUS infrequently involves the lymph nodes or other extramedullary and smoldering WM before developing clinical symptoms. sites, demonstration of BM infiltration (for example, through 2 Therefore, the identification of new objective criteria for the trephine biopsy) is therefore essential for the diagnosis of WM. differential diagnosis between these conditions, as well as more Many patients who fulfill the criteria for WM do not require accurate estimation of their risk of progression for optimal clinical immediate therapy because they are detected before developing management are mostly welcome, particularly in two settings: 3 disease-associated symptoms. These patients are classified as (i) to decide which patients are candidates for an early treatment smoldering WM, a clinically recognized entity with a cumulative intervention, and (ii) to optimize monitoring of premalignant probability of progression to symptomatic WM, amyloidosis or stages. However, the differential diagnosis among these patient lymphoma of 65% at 10 years.4 groups may be challenging as some asymptomatic cases can Smoldering WM patients have a greater risk of progression to present with markedly elevated IgM levels and BM infiltration, active disease than IgM-monoclonal gammopathy of undeter- while others show minimal tumor burden but require therapy due mined significance (MGUS) cases (18% at 10 years).5 Currently, to disease-related complications. Moreover, although serum IgM 1Hospital Universitario de Salamanca, Department of Hematology, Salamanca, Spain; 2IBSAL IBMCC (USAL-CSIC), Salamanca, Spain; 3Complejo Hospitalario de Leo´n, Leo´ n, Spain; 4Hospital Clı´nico Universitario de Valladolid, Valladolid, Spain; 5Hospital Comarcal del Bierzo, PonferradaLeo´ n, Spain; 6Hospital General de Segovia, Segovia, Spain; 7Hospital Virgen de la Concha, Zamora, Spain; 8Hospital Virgen del Puerto, Plasencia, Spain; 9Hospital Nuestra Sen˜ ora de Sonsoles, A´ vila, Spain; 10Hospital Rio Carrio´ n, Palencia, Spain; 11Hospital Santos Reyes, Aranda de Duero, Spain; 12Complejo Asistencial Universitario de Burgos, Burgos, Spain and 13Servicio General de Citometrı´a and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain. Correspondence: Professor JF San Miguel, IBSAL-Hospital Universitario de Salamanca, Paseo de San Vicente 58–182, Salamanca 37007, Spain. E-mail: [email protected] Received 12 March 2013; revised 10 April 2013; accepted 12 April 2013; accepted article preview online 24 April 2013; advance online publication, 14 May 2013 Immunophenotyping of IgM monoclonal gammopathies B Paiva et al 167 concentration is increased in WM, it may often do not exceed MFC immunophenotypic studies 2 3 g/dl, thus showing considerable overlap with IgM-MGUS; Erythrocyte-lysed whole-BM samples were immunophenotyped using similar variability has also been reported for the levels of BM 4-color combinations of the following fluorochrome-conjugated—fluores- infiltration.8–13 Finally, the differential diagnosis of WM may also cein isothiocyanate/phycoerythrin/peridinin chlorophyll protein-cyanin 5.5 be challenged by other diseases, which may also show an IgM (PerCPCy5.5)/allophycocyanin—monoclonal antibodies: cytoplasmatic Ig paraprotein (for example, IgM-MM, marginal zone, mantle cell or lambda light chain (CyIgl)/cytoplasmatic Ig kappa CyIgk/CD19/CD38, follicular lymphoma). CyBcl2/CD103/CD19/CD38, surface membrane IgM (SmIgM)/CD25/CD19/ CD38, SmIgM/CD27/CD19/CD38 CD11c/CD5/CD19/CD38, CD22/CD23/ In recent years, multiparameter flow cytometry (MFC) immuno- CD19/CD38, CD138/CD25/CD19/CD38, HLA-DR/CD11b/CD19/CD38, FMC7/ phenotyping has demonstrated to be of great value in the 14 CD24/CD19/CD38, CD45RA/CD45RO/CD19/CD38, CD38/CD10/C19/CD20, differential diagnosis of B-cell lymphoproliferative disorders, as CD38/CD56/CD19/CD45. Thus, a total of 23 different phenotypic markers, well as for baseline prognostication of patients with (non-IgM) including SmIgM, CyIgl and CyIgk were systematically evaluated in both MGUS and MM.15,16 Its use in WM was strongly recommended in BM mature B cells and PCs identified as CD19 þ /SSClow and CD38hi/SSCint the Second International WM Workshop in 2003,2 but immuno- cells, respectively, after careful exclusion of B-cell precursors (CD19 þ / hi low phenotypic studies on patients with IgM monoclonal CD38 /SSC ). A stain-and-then-lyse direct immunofluorescence techni- gammopathies remain limited, focused only on patients with que was used to evaluate all surface markers; for the staining of CyIgl, the most aggressive forms of the disease, and no consensus has CyIgk and CyBcl2, the Fix & Perm reagent kit (DAKO, Glostrup, Denmark) was used, strictly following the recommendations of the manufacturer. The been reached so far about the phenotypic characteristics of the 17–23 evaluation of SmIgM, CyIgl and CyIgk was performed after washing serum Waldenstro¨m’s clone. Ig. In all cases, one tube stained with CD19-PerCPCy5.5 and CD38-APC was Here, we report on a comprehensive immunophenotypic used for specific evaluation of baseline autofluorescence levels of B cells analysis of a large series of newly diagnosed IgM-MGUS, smolde- and PCs, respectively (negative control). ring and symptomatic WM patients. Our results show that MFC is a Data acquisition was performed in a FACSCalibur (4-color) flow valuable technique to assess the tumor burden and the degree of cytometer (Becton Dickinson Biosciences, BDB, San Jose, CA, USA) using clonality in patients’ BM aspirate, providing invaluable information the FACSDiva 6.1 software (BDB), and a two-step acquisition procedure. In 4 for the differential diagnosis of IgM-MGUS and prognostication of the first step, information about 5 Â 10 events corresponding to the WM. In addition, the specific phenotypic characteristics of clonal B whole-sample cellularity was stored; while in the second step, data about CD19 þ or CD38 þ gated events was selectively stored, for a minimum of cells and PCs are also described in detail. 106 leukocytes/tube. Data analysis was performed using the Infinicyt software (Cytognos, Salamanca, Spain). PATIENTS AND METHODS Patients Statistical analysis A total of 244 newly diagnosed patients with an IgM monoclonal The Mann–Whitney U test was used to estimate the statistical significance gammopathy—classified as IgM-MGUS (n ¼ 67), smoldering WM (n ¼ 77) of differences observed between groups. Smoldering WM patients who and symptomatic WM (n ¼ 100)—who were referred
Load more

Recommended publications
  • Noninfectious Mixed Cryoglobulinaemic Glomerulonephritis and Monoclonal Gammopathy of Undetermined Significance: a Coincidental Association? Adam L
    Flavell et al. BMC Nephrology (2020) 21:293 https://doi.org/10.1186/s12882-020-01941-3 CASE REPORT Open Access Noninfectious mixed cryoglobulinaemic glomerulonephritis and monoclonal gammopathy of undetermined significance: a coincidental association? Adam L. Flavell1* , Robert O. Fullinfaw2, Edward R. Smith1,3, Stephen G. Holt1,3, Moira J. Finlay3,4 and Thomas D. Barbour1,3 Abstract Background: Cryoglobulins are cold-precipitable immunoglobulins that may cause systemic vasculitis including cryoglobulinaemic glomerulonephritis (CGN). Type 1 cryoglobulins consist of isolated monoclonal immunoglobulin (mIg), whereas mixed cryoglobulins are typically immune complexes comprising either monoclonal (type 2) or polyclonal (type 3) Ig with rheumatoid activity against polyclonal IgG. Only CGN related to type 1 cryoglobulins has been clearly associated with monoclonal gammopathy of undetermined significance (MGUS) using the conventional serum-, urine- or tissue-based methods of paraprotein detection. Case presentation: We present four patients with noninfectious mixed (type 2 or 3) CGN and MGUS. Two patients had type 2 cryoglobulinaemia, one had type 3 cryoglobulinaemia, and one lacked definitive typing of the serum cryoprecipitate. The serum monoclonal band was IgM-κ in all four cases. Treatments included corticosteroids, cyclophosphamide, plasma exchange, and rituximab. At median 3.5 years’ follow-up, no patient had developed a haematological malignancy or advanced chronic kidney disease. Other potential causes of mixed cryoglobulinaemia were also present in our cohort, notably primary Sjögren’s syndrome in three cases. Conclusion: Our study raises questions regarding the current designation of type 2 CGN as a monoclonal gammopathy of renal significance, and the role of clonally directed therapies for noninfectious mixed CGN outside the setting of haematological malignancy.
    [Show full text]
  • Cardiac Nonamyloidotic Immunoglobulin Deposition Disease
    Modern Pathology (2006) 19, 233–237 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Cardiac nonamyloidotic immunoglobulin deposition disease Amir A Toor1,6, Ben A Ramdane1, Jacob Joseph2, Maria Thomas3, Carl O’Hara4, Bart Barlogie1, Patrick Walker5 and Lija Joseph3,4,7 1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Division of Cardiovascular Medicine, Boston University School of Medicine, Boston, MA, USA; 3Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 4Department of Pathology, Mallory Institute of Pathology, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA and 5Nephropathology Associates, Little Rock, AR, USA Cardiac nonamyloidotic immunoglobulin (Ig) deposition disease (CIDD) is a rare disorder characterized by Ig deposition in the myocardium associated with plasma cell dyscrasias. A retrospective review of cardiac biopsies performed at two different institutions identified eight patients with CIDD. All patients had plasma cell dyscrasias with monoclonal gammopathy. Three had IgG k, two had IgG j, one had IgD j and one each had free j and free k light chain. Four patients had concurrent amyloidosis involving other organs. One had amyloidosis of kidney alone, one had amyloidosis of kidney and abdominal fat pad and two others had amyloidosis of bone marrow vasculature. Three patients had dialysis-dependent renal insufficiency. None of the patients had symptoms of heart failure. Six patients had echocardiographically demonstrable concentric left ventricular hypertrophy with diastolic dysfunction. Two patients had significant cardiac arrhythmias requiring medical intervention. On endomyocardial biopsy, all eight had normal appearing myocardium on light microscopy with negative Congo Red and Thioflavin T stains.
    [Show full text]
  • Waldenstrom's Macroglobulinemia
    Review Article Open Acc Blood Res Trans J Volume 3 Issue 1 - May 2019 Copyright © All rights are reserved by Mostafa Fahmy Fouad Tawfeq DOI: 10.19080/OABTJ.2019.02.555603 Waldenstrom’s Macroglobulinemia: An In-depth Review Sabry A Allah Shoeib1, Essam Abd El Mohsen2, Mohamed A Abdelhafez1, Heba Y Elkholy1 and Mostafa F Fouad3* 1Internal Medicine Department , Faculty of Medicine, Menoufia University 2El Maadi Armed Forces Institute, Egypt 3Specialist of Internal Medicine at Qeft Teatching Hospital, Qena, Egypt Submission: March 14, 2019; Published: May 20, 2019 *Corresponding author: Mostafa Fahmy Fouad Tawfeq MBBCh, Adress: Elzaferia, Qeft, Qena, Egypt Abstract Objective: The aim of the work was to through in-depth lights on new updates in waldenstrom macroglobulinemia disease. Data sources: Data were obtained from medical textbooks, medical journals, and medical websites, which had updated with the key word (waldenstrom macroglobulinemia ) in the title of the papers. Study selection: Selection was carried out by supervisors for studying waldenstrom macroglobulinemia disease. Data extraction: Special search was carried out for the key word waldenstrom macroglobulinemia in the title of the papers, and extraction was made, including assessment of quality and validity of papers that met with the prior criteria described in the review. Data synthesis: The main result of the review and each study was reviewed independently. The obtained data were translated into a new language based on the need of the researcher and have been presented in various sections throughout the article. Recent Findings: We now know every updated information about Wald Enstrom macroglobulinemia and clinical trials. A complete understanding of the Wald Enstrom macroglobulinemia will be helpful for the future development of innovative therapies for the treatment of the disease and its complications.
    [Show full text]
  • Progression of a Solitary, Malignant Cutaneous Plasma-Cell Tumour to Multiple Myeloma in a Cat
    Case Report Progression of a solitary, malignant cutaneous plasma-cell tumour to multiple myeloma in a cat A. Radhakrishnan1, R. E. Risbon1, R. T. Patel1, B. Ruiz2 and C. A. Clifford3 1 Mathew J. Ryan Veterinary Hospital of the University of Pennsylvania, Philadelphia, PA, USA 2 Antech Diagnostics, Farmingdale, NY, USA 3 Red Bank Veterinary Hospital, Red Bank, NJ, USA Abstract An 11-year-old male domestic shorthair cat was examined because of a soft-tissue mass on the left tarsus previously diagnosed as a malignant extramedullary plasmacytoma. Findings of further diagnostic tests carried out to evaluate the patient for multiple myeloma were negative. Five Keywords hyperproteinaemia, months later, the cat developed clinical evidence of multiple myeloma based on positive Bence monoclonal gammopathy, Jones proteinuria, monoclonal gammopathy and circulating atypical plasma cells. This case multiple myeloma, pancytopenia, represents an unusual presentation for this disease and documents progression of an plasmacytoma extramedullary plasmacytoma to multiple myeloma in the cat. Introduction naemia, although it also can occur with IgG or IgA Plasma-cell neoplasms are rare in companion ani- hypersecretion (Matus & Leifer, 1985; Dorfman & mals. They represent less than 1% of all tumours in Dimski, 1992). Clinical signs of hyperviscosity dogs and are even less common in cats (Weber & include coagulopathy, neurologic signs (dementia Tebeau, 1998). Diseases represented in this category and ataxia), dilated retinal vessels, retinal haemor- of neoplasia include multiple myeloma (MM), rhage or detachment, and cardiomyopathy immunoglobulin M (IgM) macroglobulinaemia (Dorfman & Dimski, 1992; Forrester et al., 1992). and solitary plasmacytoma (Vail, 2001). These con- Coagulopathy can result from the M-component ditions can result in an excess secretion of Igs interfering with the normal function of platelets or (paraproteins or M-component) which produce a clotting factors.
    [Show full text]
  • MGUS): Diagnosis, Predictors of Progression, and Monitoring a Pocket Guide for the Clinician
    Monoclonal Gammopathy of Undetermined Significance (MGUS): Diagnosis, Predictors of Progression, and Monitoring A Pocket Guide for the Clinician DISTRIBUTION Brea C. Lipe, MD University of Rochester Medical Center Robert A. Kyle, MD Mayo Clinic, Rochester, MN November 2016 Recommendations in this guide are based on Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) FORmultiple myeloma: International Myeloma Working Group consensus perspectives risk factors for progression and guidelines for monitoring and management1 and additional sources.2,3,4,5,6 NOT Disease Definition Test Comment Monoclonal Gammopathy of Undetermined Significance (MGUS) is an Quantitative (IgG, IgA and IgM) May be suggestive of a immunoglobulins plasma cell disorder. asymptomatic condition that is included in a spectrum of monoclonal plasma cell disorders (dyscrasias). MGUS is characterized by a Serum immunoglobulin free light chains monoclonal protein (M protein) < 3 g/dL (30 g/L) in the serum and (including the ratio) < 10% monoclonal plasma cells in the bone marrow and no evidence of end-organ damage (“CRAB”: hypercalcemia, renal insufficiency, anemia or Secondary Evaluation bone lesions), lymphoma, Waldenström macroglobulinemia, or light chain Patients should undergo bone marrow aspiration and biopsy, amyloidosis (AL). Smoldering multiple myeloma (SMM) also lies along this including FISH and skeletal survey in the presence of an M-protein spectrum of plasma cell disorders, is also asymptomatic and is defined with any of the following: as having an M protein ≥ 3 g/dL (30 g/L) and/or ≥ 10% monoclonal plasma cells in the bone marrow and no CRAB features. Patients with • End-organ damage with “CRAB” features including high risk SMM may be candidates for clinical trials.
    [Show full text]
  • I M M U N O L O G Y Core Notes
    II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111
    [Show full text]
  • Type-I Cryoglobulinaemia Associated to Monoclonal Gammapathy of Undetermined Significance
    194) Prague Medical Report / Vol. 121 (2020) No. 3, p. 194–199 Type-I Cryoglobulinaemia Associated to Monoclonal Gammapathy of Undetermined Significance Juan Manuel Duarte1, Paloma Ocampo1, Silvia Graciela Ramos2, Orlando Gabriel Carballo2, Ricardo E. Barcia1, Cecilia Elena Arévalo1 1Sexta Cátedra de Medicina Interna, Hospital de Clínicas “José de San Martín”, Universidad de Buenos Aires, Buenos Aires, Argentina; 2Laboratorio de Inmunología, Unidad de Inmunología e Histocompatibilidad, Hospital Carlos G. Durand, Gobierno de la Ciudad de Buenos Aires, Buenos Aires, Argentina Received December 20, 2019; Accepted September 14, 2020. Key words: Cryoglobulinaemia – Monoclonal gammopathy of undetermined significance – Neuropathy – Vasculitis Abstract: Cryoglobulins are immunoglobulins that undergo reversible precipitation at cold temperatures. Monoclonal type-I cryoglobulinaemia is the least frequent and is associated to hematological diseases such as multiple myeloma, Waldenström’s macroglobulinaemia, chronic lymphocytic leukaemia and lymphoma. We describe the case of a 60-year-old female patient, who suffered from burning pain in her feet for ten months before her admission. The patient presented intermittent distal cyanosis that progressed to digital ischaemia. She also reported paresthesia in her hands, difficulty in writing, and a 26-kg-weight loss. At the physical examination, it was identified livedo reticularis, palpable purpura, and painful ecchymotic lesions in her calves and feet. Moreover, peripheral pulses were palpable and symmetrical. It was observed an atrophy of the right first dorsal interosseous and both extensor digitorum brevis, as well as a distal bilateral apalesthesia and allodynia. Both Achilles reflexes were absent. Laboratory tests revealed anemia, high erythrosedimentation rate and C-reactive protein. Serum protein electrophoresis showed a monoclonal IgG-Kappa gammopathy.
    [Show full text]
  • Competition Between Clonal Plasma Cells and Normal Cells for Potentially
    Leukemia (2011) 25, 697–706 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma B Paiva1,2,MPe´rez-Andre´s2,3, M-B Vı´driales1,2, J Almeida2,3, N de las Heras4, M-V Mateos1,2,LLo´pez-Corral1,2, NC Gutie´rrez1,2, J Blanco1, A Oriol5, MT Herna´ndez6, F de Arriba7, AG de Coca8, M-J Terol9, J de la Rubia10, Y Gonza´lez11, A Martı´n12, A Sureda13, M Schmidt-Hieber2,3, A Schmitz14, HE Johnsen14, J-J Lahuerta15, J Blade´16, JF San-Miguel1,2 and A Orfao2,3 on behalf of the GEM (Grupo Espan˜ol de MM)/PETHEMA (Programa para el Estudio de la Terape´utica en Hemopatı´as Malignas) cooperative study groups and the Myeloma Stem Cell Network (MSCNET) 1Servicio de Hematologı´a, Hospital Universitario de Salamanca, Salamanca, Spain; 2Servicio de Hematologia, Centro de Investigacio´n del Ca´ncer (CIC, IBMCC USAL-CSIC), Salamanca, Spain; 3Servicio General de Citometrı´a and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain; 4Servicio de Hematologı´a, Complejo Hospitalario de Leo´n, Leo´n, Spain; 5Servicio de Hematologı´a, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 6Servicio de Hematologı´a, Hospital Universitario de Canarias, Tenerife, Spain; 7Servicio de Hematologı´a, Hospital Morales Meseguer, Murcia, Spain; 8Servicio de Hematologı´a, Hospital Clı´nico Universitario de Valladolid,
    [Show full text]
  • Neuropathy in Waldenstrom Macrogolubinemia B
    NEUROPATHY IN WALDENSTROM MACROGOLUBINEMIA B. JANE DISTAD, MD ASSOCIATE PROFESSOR DEPARTMENT OF NEUROLOGY JANUARY 13, 2018 OUTLINE • Anatomy • Epidemiology • Types • Pathophysiology • Investigation • Treatment DEFINITION - NEUROPATHY • a condition that develops from disease or damage to the peripheral nervous system — the vast network that transmits information between the central nervous system (the brain and spinal cord) and every other part of the body.– [NINDS NIH] • Symptoms - numbness or tingling, pricking sensations (paresthesia) or weakness. • burning pain (especially at night), muscle wasting • Peripheral (or distal) refers to the areas furthest from the body or core MOTOR PATHWAYS https://medatrio.com/ascending-descending-tracts-of-spinal-cord/ PAIN AND TEMPERATURE PATHWAYS POSITION SENSE AND BALANCE PATHWAYS Imagequiz.co.uk ORIGIN OF THE PERIPHERAL NERVE Spinal cord •From: The Importance of Rare Subtypes in Diagnosis and Copyright © 2015 American Medical Treatment of Peripheral Neuropathy A Review JAMA Neurol. Association. All rights reserved. 2015;72(12):1510-1518. doi:10.1001/jamaneurol.2015.2347 EPIDEMIOLOGY • Precision limited given multiple different definitions & causes & reporting • Peripheral neuropathy affects at least 20 million people in the United States • Neuropathy is reported in 50% of patients with diabetes mellitus • Guillain Barre Syndrome1.5 cases/100,000/year, for example • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) affects 5 people in every 100,000 (if population of Seattle is 800,000,
    [Show full text]
  • A Case of Monoclonal Gammopathy in Extranodal Marginal Zone B-Cell Lymphoma of the Small Intestine
    Korean J Lab Med 2011;31:18-21 Case Report DOI 10.3343/kjlm.2011.31.1.18 Diagnostic Hematology KJLM A Case of Monoclonal Gammopathy in Extranodal Marginal Zone B-cell Lymphoma of the Small Intestine Do Yeun Kim, M.D.1, Yong-Seok Kim, M.D.1, Hee Jin Huh, M.D.2, Jong Sun Choi, M.D. 3, Jeong Seok Yeo, M.D.4, Beom Seok Kwak, M.D.5, and Seok Lae Chae, M.D.2 Departments of Internal Medicine1, Laboratory Medicine2, Pathology3, Nuclear Medicine4, and Surgery5, College of Medicine, Dongguk University Ilsan Hospital, Goyang, Korea Monoclonal gammopathy occurs in one-third of the patients with mucosa-associated lymphoid tissue lymphoma (MALT lympho- ma). However, monoclonal gammopathy has been rarely reported in Korea. Paraprotenemia accompanying MALT lymphoma is strongly correlated with involvement of the bone marrow, and this involvement leads to the progression of the disease. Here, we present a case of a 66-yr-old man diagnosed with IgM monoclonal gammopathy and stage IV extranodal marginal zone lympho- ma of the small intestine, with the involvement of the bone marrow. (Korean J Lab Med 2011;31:18-21) Key Words: Marginal zone B-cell lymphoma, Monoclonal gammopathy, Bone marrow INTRODUCTION tive of advanced stages of the disease [8]. In Korea, monoclonal gammopathy in MALT lymphoma Extranodal marginal zone B-cell lymphoma (ENMZL) of has been rarely reported until recently [9]. Here, we report the mucosa-associated lymphoid tissue (MALT) accounts a case of a 66-yr-old man diagnosed with IgM monoclonal for 7–8% of all newly diagnosed B-cell lymphomas [1].
    [Show full text]
  • (MGUS) and Monoclonal B-Cell Lymphocytosis (MBL), Both Before and After Premalignancy Diagnosis; and Compare Their Activity to That of the General Population
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.30.20117549; this version posted May 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort Corresponding author: Eve Roman, Epidemiology & Cancer Statistics Group, Department of Health Sciences, Seebohm Rowntree Building, University of York, YO10 5DX, UK: [email protected] Maxine Lamb1, Alexandra G Smith1, Daniel Painter1, Eleanor Kane1, Tim Bagguley1, Robert Newton1,2, Debra Howell1, Gordon Cook3, Ruth de Tute4, Andrew Rawstron4, Russell Patmore5, Eve Roman1 1 Department of Health Sciences, University of York, YO10 5DD, UK 2 Ugandan Virus Research Institute, Entebbe, Uganda 3 Department of Haematology, Leeds Cancer Centre, St James’s University Hospital, LS9 7LP, UK 4 Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, St James’s University Hospital, LS9 7LP, UK 5 Queens Centre for Oncology and Haematology, Hull University Teaching Hospitals NHS Trust, HU16 5JQ, UK NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.05.30.20117549; this version posted May 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • MGUS (Monoclonal Gammopathy)
    MGUS (Monoclonal Gammopathy) About MGUS Several disorders are associated with the presence of a monoclonal protein in the blood, including Multiple Myeloma, Lymphoma, Chronic Lymphocytic Leukaemia (CLL) and MGUS. MGUS is defined by a low level of monoclonal protein (< 30 g/L) and the absence of anaemia, hypercalcaemia, lytic bone lesions, and renal failure attributable to a plasma cell disorder. It is asymptomatic and extremely common - found in 1% of people > 25 years, 3% > 70 years, and up to 10% > 80 years of age. MGUS is a potential precursor to multiple myeloma (MM) and needs long term clinical follow-up once detected. Assessment Bloods - FBC, creatinine, calcium, albumin, serum protein electrophoresis (SPE) with immunoglobulin levels, and urine Bence-Jones Protein. If fever, malaise, bone pain, lymphadenopathy, hepatosplenomegaly, kidney problems, exclude significant causes of a monoclonal protein: Multiple Myeloma Patients may present with bone pain, lytic lesions in the bones, impaired renal function, hypercalcaemia, isolated normocytic anaemia, or pancytopenia. To diagnose, arrange the same tests as for MGUS. However, there will be higher levels of monoclonal protein plus other abnormalities, as above. Arrange urgent referral if there is associated spinal cord compression, hypercalcaemia, or renal failure. All require haematologist assessment and management Lymphoma Assess for enlarged lymph nodes and/or hepatosplenomegaly. Cytopenias may also be present. If suspected refer for Haematology assessment. CLL Associated with an elevated lymphocyte count. Manage according to the CLL pathway. Amyloidosis May be associated with: Restrictive cardiomyopathy, unexplained gastrointestinal symptoms, peripheral neuropathy and carpal tunnel syndrome. Management Calculate the risk of progression to myeloma. MGUS is asymptomatic and any significant symptom or rise in protein level indicates the need for reassessment.
    [Show full text]